May 10, 2022 4:01 pm EDT Capricor Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 03, 2022 8:30 am EDT Capricor Therapeutics to Present First Quarter 2022 Financial Results and Recent Corporate Update on May 10
Mar 29, 2022 9:00 am EDT Capricor Therapeutics to Participate in the Cantor Fitzgerald Rare Orphan Disease Summit
Mar 28, 2022 8:30 am EDT Capricor Therapeutics Reports Topline Results from Phase 2 Exploratory INSPIRE Trial in Severe Hospitalized COVID-19 Patients
Mar 11, 2022 8:00 am EST The Lancet Publishes Positive Results from Capricor Therapeutics’ Phase 2 Study Evaluating CAP-1002 in Late-Stage Duchenne Muscular Dystrophy
Mar 10, 2022 4:01 pm EST Capricor Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
Mar 03, 2022 9:15 am EST Capricor Therapeutics to Present Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Update on March 10
Mar 02, 2022 9:00 am EST Capricor Therapeutics Names Dr. Daniel Paulson as Vice President of Clinical Development
Jan 25, 2022 5:00 am EST Capricor Therapeutics and Nippon Shinyaku Enter Partnership for Exclusive Commercialization and Distribution of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy in the U.S.
Dec 13, 2021 9:15 am EST Capricor Therapeutics Announces Key Updates on its Vaccine and Therapeutic Programs for COVID-19